The head of the National Centre for Pharmaco-Economics, which advises the Health Service Executive on drug costs, has said he believes a breast cancer drug the centre has rejected at its current cost will ultimately be made available to patients.
The centre has advised the HSE to reject the drug Kadcyla, manufactured by Roche, on the basis that at a price of #$%$80,000 per course of treatment it is not cost effective.
Prof Barry said the next phase would be negotiating around the price, which he said very often resulted in reductions of about 10-20%.
These outrageous drug prices...are not for slumdawg patients and insurance payers, but fine for Slumdawg the investor
check on YTD, 12 months, 5 years, 10 years, 20 years and get back to us on what you find. Hint: it's not so good except against LJPC, a terrible company.
why aren't their executives pounding the pavement to bolster their stock price. The CEO should buy 10k shares on the open market.
They should get another interview on Cramer.
Isn't there a buyer willing to pay $50 per share?
Something needs to be done.
Yes, since they only have one strength, discovery and very early development, they don't need so many employees burning up the cash, they can wait for their partnerships to mature, partner everything out, reduce costs and either buy back stock or pay a dividend when the cash flow starts building, or just find a buyer and sell off the parts that the buyer does not want. This company should easily be worth $2BB+ (sum of parts) if SGEN is worth $5BB. They also have losses that can be carried forward to provide tax free income from Kadcyla revs.
IMGN doesn't really have a product to sell. I can imagine a PDL like scenario where IMGN lays off most of its staff and collects royalties on partnered products and gives us cash and dividends.
Do you think the IMGN exec team is heading in the right direction, doing a good job, having success, creating shareholder value, making sound business decisions? I say Heck No and it's past time for a change. Dan must go and then be replaced by Howard Pien, or someone else with a track record of success, or turnaround and sale. All shareholders should take action to push for change.
I have been trying to get the attention of this do-nothing BOD, perhaps I should switch my focus to contacting Bus Dev pros at Sanofi and Roche to start the bidding. I will not rest until the IMGN shareholders and shareholder value becomes the focus of IMGN executives and the BOD, who are only focused on personal wealth/ value.
IMGN beta coefficient is something like 1.75 which means it's much more volatile than other stocks.
For the recent price swings, it has gone down in an up market and down in a bad market so it's no wonder all the price watchers are jumping up and down like they've got hot feet.
I too have a growing concern that if one or more institutions throws in the towel on their multi million dollar IMGN investments that sub $10 will come VERY quickly. I have no dry powder to take advantage of such a scenario but I also prefer not to see IMGN down in the single digits again.
Who knows, but IMGN seems to only have one direction, down. The BOD must take action. All shareholders must apply pressure. IMGN sum of parts must be worth at least 50-100% more than the current valuation. I am tired of waiting, Junius needs to go NOW!
Biotechs are tanking today again. Is it just profit taking from last Friday's surge? Typical rotation? Typical moneypulation? Or signs of strong economy will lead to early increase in interest rates?
REGN was knocked down by analyst stating they were losing 10% of Eylea sales per month to competition. Was knocked down all the way to $276, then we learn that Sanofi increased their stake and it's back up to $315 as takeover rumors persist. This bearish call is not justified and driven by an analyst agenda in my opinion.
Sentiment: Strong Buy
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
i send a email to IR of Immunogen. (BOD must take action, fire D.Junius and the most of corporate officers or sell the company)
every shareholder shoud do the same this weekend.
Same thoughts but decided to wait on quaterly results on july 28th before selling
I must admit I'm thinking the same thing. I am wondering when institutions decide to pull the plug and cash out, I'd rather get out with 11 dollars than 9 dollars.